Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
18.25
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 13, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
November 12, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
3 Under-the-Radar Healthcare Companies
November 11, 2024
While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.
Via
MarketBeat
A Preview Of Travere Therapeutics's Earnings
October 30, 2024
Via
Benzinga
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
October 21, 2024
Via
Benzinga
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
October 16, 2024
Via
Benzinga
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
November 07, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
November 04, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
October 10, 2024
Via
Benzinga
Where Travere Therapeutics Stands With Analysts
September 27, 2024
Via
Benzinga
Analyst Ratings For Travere Therapeutics
September 06, 2024
Via
Benzinga
Travere Therapeutics Reports Third Quarter 2024 Financial Results
October 31, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024
October 26, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
October 23, 2024
Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker.
Via
Benzinga
Travere Therapeutics to Report Third Quarter 2024 Financial Results
October 21, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 17, 2024
Via
Benzinga
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
October 17, 2024
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 14, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm
October 11, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease
October 09, 2024
The company could soon ask for approval of its only drug, Filspari, in a second disease.
Via
Investor's Business Daily
Exposures
Product Safety
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
September 27, 2024
Via
Benzinga
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
September 27, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
September 26, 2024
Via
Benzinga
Travere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3 HARMONY Study of Pegtibatinase Related to Commercial Manufacturing Scale-Up
September 26, 2024
Company to host conference call today at 4:30 p.m. ET
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at the 2024 Cantor Global Healthcare Conference
September 10, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
September 09, 2024
Via
Benzinga
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
September 06, 2024
Via
Benzinga
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
September 06, 2024
The company previously had an accelerated approval for its IgA nephropathy treatment.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
